WuXi AppTec shares rally as FY profit more than doubles

Net profit attributable to shareholders more than doubled to ¥19.19bn in 2025 while revenue rose 15.8% to ¥45.46bn; adjusted non‑IFRS net profit increased 41.3% to ¥14.96bn and gross margin widened to 47.0% (from 40.8%). WuXi Chemistry revenue jumped 25.5% and U.S. customer revenue climbed 34.3%, backlog grew 28.8% to ¥58bn. Management guided 2026 revenue of ¥51.3–53.0bn (implying +18–22% growth) and proposed a final cash dividend of ¥15.7927 per 10 shares; Hong Kong shares rallied up to 10% (Shanghai ~7%).

Analysis

WuXi’s upgrade in mix toward late‑stage and commercial work creates durable pricing power that is easily underestimated. Higher margin, repeatable commercial projects shorten revenue visibility but also concentrate execution risk: capacity constraints will force either accelerated capital spending (compressing near‑term FCF) or higher pricing (helping margins but risking share gains). Expect supplier winners in lab automation, high‑throughput analytics and reagent vendors — resource‑light software/AI players that speed IND/CMC filings will also capture disproportionate surplus value.

Geopolitics and regulatory cadence are the dominant tail risks on a 3–18 month horizon. A tightening of export controls or elevated inspection frequency from Western regulators could reduce U.S. client throughput materially and reprice multiples quickly; conversely, sustained conversion of backlog to revenue over 2–4 quarters would mechanically rebase consensus EPS and justify premium valuation. Near‑term catalysts to track: large commercial program starts, new long‑term capacity commitments, and quarterly organic revenue conversion rates.

The market is polarized between growth multiple expansion and capital intensity concerns. The upside case requires margin retention as late‑stage work scales; the downside is a multi‑quarter margin normalization if capex accelerates or pricing softens. Tradeable inefficiencies will appear around quarterly updates and any commentary on capacity/utilization — these are the highest information‑content events for asymmetric positioning.

Key Decisions for Investors

• Long 603259 (Shanghai A) — 6–12 month horizon: allocate 2–3% NAV, target +30% upside, stop at -15%. Enter on a <10% pullback from recent highs or immediately if you get confirmation of sequential backlog conversion in next quarter. Rationale: convexity to margin expansion if commercial mix sustains; hedge macro/regulatory event risk separately.
• Pair trade: Long 603259 (equal notional) / Short CTLT (Catalent) — 6–12 months. Expect Asian lower‑cost scale + client diversification to out‑perform legacy Western CDMOs by 20–30% on a relative basis if offshore outsourcing trend continues; cut pair if U.S. onshoring legislation passes or if both names report synchronized demand weakness.
• Options sleeve on HK listing (if liquid): buy a 9–12 month call spread (debit) to capture upside while capping premium — e.g., buy ATM call, sell 20–30% OTM call. This reduces theta bleed versus naked calls and preserves upside if margins surprise positively.
• Risk hedge: buy 3–6 month puts on a China biotech/small‑cap ETF or establish a USD/CNH FX hedge sized to expected U.S. revenue exposure if regulatory headlines intensify. Trigger unwind: when company issues explicit client continuity language or provides multi‑quarter conversion cadence.